CIK 0001743881
- Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- 4 Grant or award Director acquired 3,990 shares (grant or award)
- 4 Grant or award Director acquired 3,990 shares (grant or award)
- 4 Grant or award Director acquired 3,990 shares (grant or award)
- 4 Grant or award Director acquired 3,990 shares (grant or award)
- 4 Grant or award Director acquired 3,990 shares (grant or award)
- 4 Shares withheld for taxes Director gave up 788 shares (to pay taxes)
- 4 Planned sale Director sold 90,240 shares at an average $66.62 ($6,012,157)
- 4 Planned sale Chief Executive Officer sold 80,000 shares at an average $67.67 ($5,413,289)
- 4 Planned sale Chief Executive Officer sold 26,103 shares at an average $69.44 ($1,812,522)
- 4 Planned sale President and CFO sold 13,651 shares at an average $65.08 ($888,419)
- 4 Shares withheld for taxes Chief Executive Officer gave up 36,236 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Accounting Officer gave up 4,714 shares (to pay taxes)
- 4 Planned sale Director sold 10,000 shares at an average $67.15 ($671,456)
- 4 Planned sale Chief Executive Officer sold 80,000 shares at an average $67.40 ($5,392,243)
- 4 Planned sale Chief Accounting Officer sold 2,000 shares at $71.58 ($143,160)
- 4 Planned sale Chief Executive Officer sold 80,000 shares at an average $74.61 ($5,968,780)
- 4 Grant or award President and CFO acquired 59,041 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 14,170 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Executive Officer sold 80,000 shares at an average $68.76 ($5,501,068)
Page 2 of 23 · 453 filings